Back

Select your region

Corporate

europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Schedule a cord blood consultation

Make an appointment

Contact us today!

Want to learn more about our services? Complete the form below and we will contact you as soon as possible to provide you with all the information you need and answer your questions.

    We kindly inform you that the personal data provided in the form will be processed by Polski Bank Komórek Macierzystych Sp. z o.o. ("PBKM") with its registered office in Warsaw, Al. Jana Pawła II 29 for telephone contact in connection with the provision of information on the service.

    Summary of patients treated

    Stem Cells
    Therapies

    Stem Cells Therapies

    The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

    FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

    Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

    Check the full list of patients who received stem cell therapy derived from FamiCord labs.

    List last update: 06.2026

    List of patients who received stem cells from FamiCord Group laboratories

    List of patients who received stem cells from FamiCord Group laboratories
    Lp. Source Source type Diagnosis Medical field Year of application Therapy Country Age of recipient
    301 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 66
    302 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 63
    303 Apheresis Allogeneic T -Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 45
    304 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Croatia 57
    305 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
    306 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Kazachstan 8
    307 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
    308 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
    309 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 68
    310 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 65
    311 Apheresis Allogeneic Diffuse Large B-Cell Lymphoma Hematology 2026 Standard Therapy Germany 63
    312 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 66
    313 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 44
    314 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 57
    315 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy UK 62
    316 Apheresis Allogeneic Aplastic Anemia Hematology 2026 Standard Therapy Poland 22
    317 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
    318 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 68
    319 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Belgium 63
    320 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 47
    321 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 51
    322 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 70
    323 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 28
    324 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    325 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 73
    326 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
    327 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 10
    328 Apheresis Allogeneic T-cell non-Hodgkin lymphoma / NK Hematology 2026 Standard Therapy Poland 19
    329 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Belgium 48
    330 Apheresis Allogeneic Essential Thrombocythemia Hematology 2026 Standard Therapy USA 59
    331 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Ukraine 58
    332 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
    333 Apheresis Allogeneic B-ALL B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Netherlands 71
    334 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 59
    335 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 67
    336 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
    337 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 37
    338 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 66
    339 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 48
    340 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 15
    341 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2026 Standard Therapy USA 45
    342 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 61
    343 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 43
    344 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 64
    345 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 29
    346 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 69
    347 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 61
    348 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
    349 Apheresis Allogeneic Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML) Hematology 2026 Standard Therapy Germany 36
    350 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 66
    351 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 66
    352 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
    353 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 51
    354 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 25
    355 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 35
    356 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Finland 40
    357 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 49
    358 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
    359 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 67
    360 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 50
    361 Apheresis Allogeneic T Lymphblastic Leukemia/Lymphoma Hematology 2026 Standard Therapy Canada 43
    362 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 74
    363 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 67
    364 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 59
    365 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 44
    366 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy Poland 56
    367 Apheresis Autologous Anaplastic T Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Portugal 23
    368 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
    369 Apheresis Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 55
    370 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    371 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
    372 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 56
    373 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
    374 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 60
    375 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 75
    376 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 58
    377 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 74
    378 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    379 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 70
    380 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 25
    381 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Sweden 65
    382 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 72
    383 Apheresis Allogeneic Lymphoma Burkitt Histiocytic Sarcoma Hematology 2026 Standard Therapy Greece 12
    384 Apheresis Allogeneic Acute Myelogenous Leukaemia Hematology 2026 Standard Therapy France 69
    385 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 69
    386 Apheresis Allogeneic Acute Myeloid Leukemia FLT3-ITD positive Hematology 2026 Standard Therapy Romania 11
    387 Apheresis Allogeneic Myelofibrosis (MF) Hematology 2026 Standard Therapy Lithuania 67
    388 Apheresis Allogeneic X-ALD (E 71.3) Hematology 2026 Standard Therapy Czechia 5
    389 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
    390 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 36
    391 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 56
    392 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
    393 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 39
    394 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 24
    395 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
    396 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
    397 Apheresis Allogeneic Other Malignancy Hematology 2026 Standard Therapy USA 71
    398 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 62
    399 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
    400 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 70